The main focus of the Genomics Shared Resource (GSR) is to provide expertise and comprehensive service in the area of microarray- and next-generation sequencing (NGS)-based genomics research in both a highly accessible and cost-effective manner for Cancer Center members. The GSR, originally named as the Gene Expression Resource, has been an active Shared Resource in the Cancer Center since the first application for NCI designation in 2001. Since then, we have expanded our portfolio of services to encompass nearly every level of genomics ranging from analysis of cancer genomes with single-base resolution up through standard mRNA and miRNA expression profiling. These also include single nucleotide polymorphism genotyping, epigenomics, and analyses for transcript splice variants, fusion genes, and genomic instability. The GSR has strived to provide our researchers with direct access to the most contemporary genomic applications and state-of-the-art instrumentation. Towards this goal, we possess the capacity to perform profiling on most of the common commercially-available microarray platforms (e.g., Affymetrix, Agilent, lllumina) as well as custom-designed ones. Having recently acquired an lllumina Genome Analyzer llx NGS system, the GSR now also provides this exciting state-of-the-art profiling technology. Importantly, all of these applications can be utilized for translational research as a result of our development of optimized protocols for the analysis of samples from a broad range of sources and of extremely limited amounts. To complement these services and to help achieve productive outcomes from genomics experiments, the GSR also provides extensive data analysis and integrative bioinformatics support and routinely assists in the preparation of the appropriate sections of manuscripts and grant proposals. Taken together, the GSR provides a complete integrative and functional molecular profiling solution to the Cancer Center.
This resource provides leading technologies for the analysis of genes, gene expressions, and DNA-related, cellular material used in examining cancer cells and comparing them to normal cells to gain insights into the cellular processes, events, and materials implicated in cancer. Thus it improves the scientific quality of cancer research and ultimately the development of more effective cancer therapies.
|Semrad, Thomas; Barzi, Afsaneh; Lenz, Heinz-Josef et al. (2015) Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol 20:518-24|
|Brostoff, Terza; Dela Cruz Jr, Florante N; Church, Molly E et al. (2014) The raccoon polyomavirus genome and tumor antigen transcription are stable and abundant in neuroglial tumors. J Virol 88:12816-24|
|Kirschbaum, Mark H; Foon, Kenneth A; Frankel, Paul et al. (2014) A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma 55:2301-4|
|Mayadev, Jyoti; Qi, Lihong; Lentz, Susan et al. (2014) Implant time and process efficiency for CT-guided high-dose-rate brachytherapy for cervical cancer. Brachytherapy 13:233-9|
|Daly, Megan E; Beckett, Laurel A; Chen, Allen M (2014) Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer? Pract Radiat Oncol 4:240-6|
|Li, Tianhong; Maus, Martin K H; Desai, Sonal J et al. (2014) Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol 9:18-25|
|Campbell, Mel; Kim, Kevin Y; Chang, Pei-Ching et al. (2014) A lytic viral long noncoding RNA modulates the function of a latent protein. J Virol 88:1843-8|
|Li, Tianhong; Kung, Hsing-Jien; Mack, Philip C et al. (2013) Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 31:1039-49|
|Semrad, Thomas J; Eddings, Courtney; Dutia, Mrinal P et al. (2013) Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. Anticancer Drugs 24:636-40|
|Maus, Martin K H; Mack, Philip C; Astrow, Stephanie H et al. (2013) Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol 8:582-6|
Showing the most recent 10 out of 84 publications